• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Apollo Medical Holdings Inc.

    11/17/23 4:58:31 PM ET
    $AMEH
    Professional Services
    Consumer Discretionary
    Get the next $AMEH alert in real time by email
    S-8 1 tm2330750d1_s8.htm FORM S-8

     

    As filed with the Securities and Exchange Commission on November 17, 2023

     

    Registration No. 333- 

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM S-8

    REGISTRATION STATEMENT

     Under

    THE SECURITIES ACT OF 1933

     

    Apollo Medical Holdings, Inc.

    (Exact Name of Registrant as Specified in its Charter)

     

    Delaware
    (State or other jurisdiction of incorporation or
    organization)
    95-4472349
    (I.R.S. Employer Identification No.)

     

    1668 S. Garfield Avenue, 2nd Floor

    Alhambra, California 91801

    (Address of principal executive offices) (Zip code)

     

     

    Apollo Medical Holdings, Inc. Employment Inducement Award Plan

    (Full title of the plan)

     

    Thomas Lam

    Co-Chief Executive Officer and President

    Apollo Medical Holdings, Inc.

    1668 S. Garfield Avenue, 2nd Floor

    Alhambra, California 91801

    (626) 282-0288

    (Name, address, and telephone number, including area code, of agent for service)

     

    Copies to:

    Jurgita Ashley

    Thompson Hine LLP

    3900 Key Center

    27 Public Square

    Cleveland, Ohio 44114

    (216) 566-5500

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer x Accelerated filer ¨
    Non-accelerated filer ¨ Smaller reporting company ¨
        Emerging growth company ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ¨

     

     

     

     

     

     

    PART I

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

     

    The documents containing the information specified in Part I of Form S-8 will be sent or given to participants, as specified by Rule 428(b)(1) under the Securities Act of 1933, as amended (the “Securities Act”). Such documents need not be filed with the Securities and Exchange Commission (the “Commission”) either as part of this Registration Statement on Form S-8 (“Registration Statement”) or as prospectuses or prospectus supplements pursuant to Rule 424 under the Securities Act. These documents and the documents incorporated by reference in this Registration Statement pursuant to Item 3 of Part II of Form S-8, taken together, will constitute a prospectus that meets the requirements of Section 10(a) of the Securities Act.

     

    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3.Incorporation of Documents by Reference.

     

    The following documents, which have previously been filed by Apollo Medical Holdings, Inc. (the “Registrant”) with the Commission pursuant to the Securities Exchange Act of 1934, as amended (the “Exchange Act”), are incorporated herein by reference:

     

    ·the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2022, filed with the Commission on March 1, 2023 (including the information incorporated by reference therein from the Registrant’s Definitive Proxy Statement on Schedule 14A, filed on April 28, 2023), as amended by Amendment No. 1 on Form 10-K/A, filed with the Commission on August 9, 2023;

     

    ·the Registrant’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2023, filed with the Commission on May 10, 2023, as amended by Amendment No. 1 on Form 10-Q/A, filed with the Commission on August 9, 2023, Quarterly Report on Form 10-Q for the quarter ended June 30, 2023, filed with the Commission on August 9, 2023, and Quarterly Report on Form 10-Q for the quarter ended September 30, 2023, filed with the Commission on November 9, 2023;

     

    ·the Registrant’s Current Reports on Form 8-K filed with the Commission on January 11, 2023, February 8, 2023, February 23, 2023, March 13, 2023, May 8, 2023, June 7, 2023, June 16, 2023, July 12, 2023, July 31, 2023, August 7, 2023 (first filing), August 7, 2023 (second filing) (as amended by the Form 8-K/A filed August 9, 2023), September 8, 2023, September 13, 2023, November 7, 2023 (first filing), November 7, 2023 (second filing), November 7, 2023 (third filing), November 7, 2023 (fourth filing), and November 17, 2023 (excluding any information furnished in such reports under Item 2.02, Item 7.01 or Item 9.01); and

     

    ·the description of the Registrant’s common stock set forth in Exhibit 4.10 of the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2019, together with any amendment or report filed with the Commission for the purpose of updating such description.

     

    All documents filed by the Registrant with the Commission pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act (other than those furnished pursuant to Item 2.02 or Item 7.01 of Form 8-K or other information “furnished” to the Commission) subsequent to the filing of this Registration Statement and prior to the filing of a post-effective amendment that indicates that all securities offered have been sold or that deregisters all securities then remaining unsold will be deemed to be incorporated by reference in this Registration Statement and to be part hereof from the date of filing of such documents. Any statement contained in any document incorporated or deemed to be incorporated by reference herein will be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed document that also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded will not be deemed, except as modified or superseded, to constitute a part of this Registration Statement.

     

    1

     

     

    Item 4.Description of Securities. 

     

    Not applicable.

     

    Item 5.Interests of Named Experts and Counsel.

     

    Not applicable.

     

    Item 6.Indemnification of Directors and Officers.

     

    Section 102 of the Delaware General Corporation Law (the “DGCL”) permits a corporation to, among other things, eliminate the personal liability of directors of a corporation to the corporation or its stockholders for monetary damages for a breach of fiduciary duty as a director, except where the director breached his or her duty of loyalty, failed to act in good faith, engaged in intentional misconduct or knowingly violated a law, authorized the payment of a dividend or approved a stock repurchase in violation of Delaware corporate law or obtained an improper personal benefit.

     

    Section 145 of the DGCL provides that a corporation has the power to indemnify a director, officer, employee, or agent of the corporation, or a person serving at the request of the corporation for another corporation, partnership, joint venture, trust or other enterprise in related capacities, against expenses (including attorneys’ fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by the person in connection with any threatened, pending or completed action, suit or proceeding to which he or she was or is a party, or is threatened to be made a party, by reason of such position, if such person acted in good faith and in a manner such person reasonably believed to be in or not opposed to the best interests of the corporation, and, in any criminal action or proceeding, had no reasonable cause to believe such person’s conduct was unlawful, except that, in the case of actions brought by or in the right of the corporation, no indemnification will be made with respect to any claim, issue or matter as to which such person has been adjudged to be liable to the corporation unless and only to the extent that the Delaware Court of Chancery or other adjudicating court determines that, despite the adjudication of liability but in view of all of the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which the Delaware Court of Chancery or such other court deems proper.

     

    The Registrant’s Restated Bylaws, as amended, allow for, and the Registrant’s Restated Certificate of Incorporation, as amended (the “Certificate of Incorporation”), provides for, indemnification of the Registrant’s current and former directors, officers, committee members or representatives to the fullest extent permitted by the DGCL. In addition, the Registrant’s Certificate of Incorporation provides that, to the fullest extent permitted by the DGCL, a director of the Registrant shall not be personally liable to the Registrant or its stockholders for monetary damages for breach of fiduciary duty as a director. These indemnification provisions may be sufficiently broad to permit indemnification of the Registrant’s officers and directors for liabilities (including reimbursement of expenses incurred) arising under the Securities Act.

     

    The Registrant has entered into indemnification agreements with certain directors and executive officers to provide these directors and executive officers additional contractual assurances regarding the scope of the indemnification set forth in the Certificate of Incorporation and to provide additional procedural protections. The Registrant’s directors and officers are also covered by insurance policies maintained by the Registrant against certain liabilities for actions taken in their capacities as such, including liabilities under the Securities Act.

     

    Item 7.Exemption from Registration Claimed.

     

    Not applicable.

     

    2

     

     

    Item 8.Exhibits.

     

    Exhibit No.   Description
    4.1   Restated Certificate of Incorporation (incorporated herein by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed on January 21, 2015).
    4.2   Certificate of Amendment of Restated Certificate of Incorporation (incorporated herein by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed on April 27, 2015).
    4.3   Certificate of Amendment of Restated Certificate of Incorporation (incorporated herein by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed on December 13, 2017).
    4.4   Certificate of Amendment of Restated Certificate of Incorporation (incorporated herein by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed June 21, 2018).
    4.5   Restated Bylaws (as amended) (incorporated herein by reference to Exhibit 3.2 to the Registrant’s Quarterly Report on Form 10-Q filed on May 15, 2018).
    4.6   Amendment to Sections 3.1 and 3.2 of Article III of Restated Bylaws (incorporated herein by reference to Exhibit 3.2 to the Registrant’s Current Report on Form 8-K filed on June 21, 2018).
    4.7   Certificate of Designation of Series A Convertible Preferred Stock (incorporated herein by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed on October 19, 2015).
    4.8   Amended and Restated Certificate of Designation (incorporated herein by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed on April 4, 2016).
    5.1   Opinion of Thompson Hine LLP.
    23.1   Consent of Independent Registered Public Accounting Firm.
    23.2   Consent of Thompson Hine LLP (included in Exhibit 5.1).
    24.1   Power of Attorney (included in the signature page to this Registration Statement).
    99.1   Apollo Medical Holdings, Inc. Employment Inducement Award Plan (incorporated herein by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed on November 17, 2023).
    99.2   Form of Stock Option Agreement (Employment Inducement Award Plan) (incorporated herein by reference to Exhibit 10.2 to the Registrant’s Current Report on Form 8-K filed on November 17, 2023).
    99.3   Form of Restricted Stock Agreement (Employment Inducement Award Plan) (incorporated herein by reference to Exhibit 10.3 to the Registrant’s Current Report on Form 8-K filed on November 17, 2023).
    107   Filing Fee Table.

     

    Item 9.Undertakings.

     

    (a) The undersigned Registrant hereby undertakes:

     

    (1) To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:

     

    (i) To include any prospectus required by Section 10(a)(3) of the Securities Act;

     

    (ii) To reflect in the prospectus any facts or events arising after the effective date of the Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20% change in the maximum aggregate offering price set forth in the “Calculation of Filing Fee Tables” or “Calculation of Registration Fee” table, as applicable, in the effective registration statement; and

     

    (iii) To include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to such information in the Registration Statement;

     

    3

     

     

    provided, however, that paragraphs (a)(1)(i) and (a)(1)(ii) do not apply if the registration statement is on Form S-8, and the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in the Registration Statement.

     

    (2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    (3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

     

    (b) The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the Registration Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    (c) Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue. 

     

    4

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Alhambra, State of California, on November 17, 2023. 

     

      APOLLO MEDICAL HOLDINGS, INC.
         
      By: /s/ Thomas Lam                            
        Thomas Lam, M.D., M.P.H.
        Co-Chief Executive Officer and President
        (Principal Executive Officer)
         
      By: /s/ Brandon Sim
        Brandon Sim
        Co-Chief Executive Officer
        (Principal Executive Officer)

     

    5

     

     

    POWER OF ATTORNEY

     

    Each person whose signature appears below constitutes and appoints each of Thomas S. Lam, M.D., M.P.H. and Brandon Sim, acting alone or together with another attorney-in-fact, as his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for such person and in his or her name, place and stead, and in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, and any subsequent registration statements pursuant to Rule 462 of the Securities Act, with the Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite or necessary to be done in and about the premises, as fully and to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

     

    SIGNATURE   TITLE   DATE
               
    By: /s/ Thomas S. Lam   Co-Chief Executive Officer (Principal Executive Officer), President, and Director   November 17, 2023
      Thomas S. Lam, M.D., M.P.H.      
               
    By: /s/ Brandon Sim   Co-Chief Executive Officer (Principal Executive Officer)   November 17, 2023
      Brandon Sim      
               
    By: /s/ Chandan Basho   Chief Financial Officer and Chief Strategy Officer (Principal Financial Officer)   November 17, 2023
      Chandan Basho      
               
    By: /s/ John Vong   Chief Accounting Officer (Principal Accounting Officer)   November 17, 2023
      John Vong      
               
    By: /s/ Kenneth Sim   Executive Chairman, Director   November 17, 2023
      Kenneth Sim, M.D.        
               
    By: /s/ John Chiang   Director   November 17, 2023
      John Chiang        
               
    By: /s/ Weili Dai   Director   November 17, 2023
      Weili Dai        
               
    By: /s/ J. Lorraine Estradas   Director   November 17, 2023
      J. Lorraine Estradas, R.N., B.S.N., M.P.H.        
               
    By: /s/ Mitchell W. Kitayama   Director    November 17, 2023
      Mitchell W. Kitayama        
               
    By: /s/ Linda Marsh   Director   November 17, 2023
      Linda Marsh        
               
    By: /s/ Matthew Mazdyasni   Director   November 17, 2023
      Matthew Mazdyasni        
               
    By: /s/ David G. Schmidt   Director   November 17, 2023
      David G. Schmidt        

     

    6

     

    Get the next $AMEH alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AMEH

    DatePrice TargetRatingAnalyst
    2/22/2024$44.00 → $55.00Neutral → Buy
    BofA Securities
    1/24/2024$45.00Buy
    Stifel
    12/22/2023$41.00Hold
    Truist
    10/17/2023$45.00Buy
    BTIG Research
    4/12/2023$44.00Neutral
    BofA Securities
    12/19/2022$40.00Buy
    Lake Street
    9/21/2022Outperform
    William Blair
    1/11/2022$93.00Buy
    Colliers Securities
    More analyst ratings

    $AMEH
    SEC Filings

    See more
    • Apollo Medical Holdings Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits

      8-K - Astrana Health, Inc. (0001083446) (Filer)

      2/29/24 6:03:30 AM ET
      $AMEH
      Professional Services
      Consumer Discretionary
    • Apollo Medical Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Astrana Health, Inc. (0001083446) (Filer)

      2/27/24 4:19:15 PM ET
      $AMEH
      Professional Services
      Consumer Discretionary
    • Apollo Medical Holdings Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

      8-K - Astrana Health, Inc. (0001083446) (Filer)

      2/26/24 6:04:01 AM ET
      $AMEH
      Professional Services
      Consumer Discretionary

    $AMEH
    Financials

    Live finance-specific insights

    See more
    • Apollo Medical Holdings, Inc. Schedules 2023 Fourth Quarter and Full Year Financial Results Release and Conference Call

      ALHAMBRA, Calif., Jan. 31, 2024 /PRNewswire/ -- Apollo Medical Holdings, Inc. ("ApolloMed," and together with its subsidiaries and affiliated entities, the "Company") (NASDAQ:AMEH), a leading provider-centric, technology-powered healthcare company enabling providers to deliver accessible, high-quality, and high-value care to all, today announced that it will release financial results for the fourth quarter and full year ended December 31, 2023, after the close of the stock market on Tuesday, February 27, 2024. The Company will discuss those results on a conference call at 2:30 p.m. PT/5:30 p.m. ET that same day.

      1/31/24 8:00:00 AM ET
      $AMEH
      Professional Services
      Consumer Discretionary
    • Apollo Medical Holdings, Inc. Reports Second Quarter 2023 Results

      Company to Host Conference Call on Monday, August 7, 2023, at 2:30 p.m. PT/5:30 p.m. ET ALHAMBRA, Calif., Aug. 7, 2023 /PRNewswire/ -- Apollo Medical Holdings, Inc. ("ApolloMed," and together with its subsidiaries and affiliated entities, the "Company") (NASDAQ:AMEH), a leading physician-centric, technology-powered healthcare company focused on enabling providers in the successful delivery of value-based care, today announced its consolidated financial results for the second quarter ended June 30, 2023. Brandon Sim, Co-Chief Executive Officer of ApolloMed, stated, "Our strong

      8/7/23 5:17:00 PM ET
      $AMEH
      Professional Services
      Consumer Discretionary
    • Apollo Medical Holdings, Inc. Schedules 2023 Second Quarter Financial Results Release and Conference Call

      ALHAMBRA, Calif., July 28, 2023 /PRNewswire/ -- Apollo Medical Holdings, Inc. ("ApolloMed," and together with its subsidiaries and affiliated entities, the "Company") (NASDAQ:AMEH), a leading physician-centric, technology-powered healthcare company focused on enabling providers in the successful delivery of value-based care, today announced that it will release financial results for the second quarter ended June 30, 2023, after the close of the stock market on Monday, August 7, 2023. The Company will discuss those results in a conference call at 2:30 p.m. PT/5:30 p.m. ET that same day.

      7/28/23 8:05:00 AM ET
      $AMEH
      Professional Services
      Consumer Discretionary

    $AMEH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Apollo Medical Holdings Inc. (Amendment)

      SC 13G/A - Apollo Medical Holdings, Inc. (0001083446) (Subject)

      2/13/24 4:58:57 PM ET
      $AMEH
      Professional Services
      Consumer Discretionary
    • SEC Form SC 13D/A filed by Apollo Medical Holdings Inc. (Amendment)

      SC 13D/A - Apollo Medical Holdings, Inc. (0001083446) (Subject)

      11/17/23 4:15:14 PM ET
      $AMEH
      Professional Services
      Consumer Discretionary
    • SEC Form SC 13G/A filed by Apollo Medical Holdings Inc. (Amendment)

      SC 13G/A - Apollo Medical Holdings, Inc. (0001083446) (Subject)

      2/9/23 11:07:39 AM ET
      $AMEH
      Professional Services
      Consumer Discretionary

    $AMEH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Kumar Dinesh M. was granted 150,395 shares (SEC Form 4)

      4 - Apollo Medical Holdings, Inc. (0001083446) (Issuer)

      1/24/24 4:31:15 PM ET
      $AMEH
      Professional Services
      Consumer Discretionary
    • SEC Form 3 filed by new insider Kumar Dinesh M.

      3 - Apollo Medical Holdings, Inc. (0001083446) (Issuer)

      1/24/24 4:30:18 PM ET
      $AMEH
      Professional Services
      Consumer Discretionary
    • Vong John was granted 14,352 shares, increasing direct ownership by 293% to 19,253 units (SEC Form 4)

      4 - Apollo Medical Holdings, Inc. (0001083446) (Issuer)

      12/19/23 9:10:18 PM ET
      $AMEH
      Professional Services
      Consumer Discretionary

    $AMEH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Apollo Medical upgraded by BofA Securities with a new price target

      BofA Securities upgraded Apollo Medical from Neutral to Buy and set a new price target of $55.00 from $44.00 previously

      2/22/24 9:10:05 AM ET
      $AMEH
      Professional Services
      Consumer Discretionary
    • Stifel initiated coverage on Apollo Medical with a new price target

      Stifel initiated coverage of Apollo Medical with a rating of Buy and set a new price target of $45.00

      1/24/24 6:57:05 AM ET
      $AMEH
      Professional Services
      Consumer Discretionary
    • Truist initiated coverage on Apollo Medical with a new price target

      Truist initiated coverage of Apollo Medical with a rating of Hold and set a new price target of $41.00

      12/22/23 7:19:49 AM ET
      $AMEH
      Professional Services
      Consumer Discretionary

    $AMEH
    Leadership Updates

    Live Leadership Updates

    See more

    $AMEH
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • ApolloMed and BASS Medical Group to Forge a Value-Based Healthcare Partnership

      ALHAMBRA, Calif., Jan. 29, 2024 /PRNewswire/ -- Apollo Medical Holdings, Inc.("ApolloMed," and together with its subsidiaries and affiliated entities, the "Company") (NASDAQ:AMEH), a leading provider-centric, technology-powered healthcare company enabling providers to deliver accessible, high-quality, and high-value care to all, today announced a strategic long-term partnership with BASS Medical Group, one of the largest multi-specialty medical groups in the Greater San Francisco Bay Area. The partnership will bolster BASS Medical Group's value-based care and operational infra

      1/29/24 8:00:00 AM ET
      $AMEH
      Professional Services
      Consumer Discretionary
    • Akido Appoints Eric Chin as its first Chief Financial Officer As the Company Prepares to Accelerate Growth

      LOS ANGELES, Jan. 31, 2023 (GLOBE NEWSWIRE) -- Akido, a tech-integrated medical network reimagining healthcare from the ground up, announced that Eric Chin has been appointed Chief Financial Officer, effective immediately. Chin will work closely with Akido's co-founders as the company continues to bring its unique blend of AI-powered technology, best-in-class medical services and scalable preventive care programs to new markets across the U.S. Previously, Chin served as Chief Financial Officer at Apollo Medical Holdings (ApolloMed), a publicly traded physician-centric technology-powered healthcare company (NASDAQ:AMEH) that increased reported total revenue from approximately $520 million i

      1/31/23 9:30:00 AM ET
      $AMEH
      Professional Services
      Consumer Discretionary
    • The Oncology Institute Names Mihir Shah as Chief Financial Officer

      CERRITOS, Calif., April 04, 2022 (GLOBE NEWSWIRE) -- The Oncology Institute of Hope and Innovation (NASDAQ:TOI) today announced the appointment of Mihir Shah as chief financial officer, effective immediately. In this role, Mr. Shah will lead the Accounting, Finance, Revenue Cycle Management, and Investor Relations functions, playing a key role in driving TOI's public company success and executing the strategic growth plan. Mr. Shah succeeds Scott Dalgleish, who will serve as a senior advisor through a transition period. Mr. Shah joins TOI with fifteen years of industry leadership experience across public, private, and not-for-profit organizations. Most recently Mr. Shah served as chief fi

      4/4/22 6:01:00 AM ET
      $AMEH
      $TOI
      Professional Services
      Consumer Discretionary
      Medical/Nursing Services
      Health Care
    • Apollo Medical Holdings, Inc. Becomes Astrana Health, Inc.

      ALHAMBRA, Calif., Feb. 22, 2024 /PRNewswire/ -- Apollo Medical Holdings, Inc.("ApolloMed," and together with its subsidiaries and affiliated entities, the "Company") (NASDAQ:AMEH), a leading provider-centric, technology-powered healthcare company enabling providers to deliver accessible, high-quality, and high-value care to all, announced today it will formally change its name from Apollo Medical Holdings, Inc. ("ApolloMed") to Astrana Health, Inc. ("Astrana Health"). As previously announced, the Company will begin trading under the ticker symbol "ASTH." Both changes will take effect February 26, 2024.

      2/22/24 8:00:00 AM ET
      $AMEH
      Professional Services
      Consumer Discretionary
    • Apollo Medical Holdings, Inc. Schedules 2023 Fourth Quarter and Full Year Financial Results Release and Conference Call

      ALHAMBRA, Calif., Jan. 31, 2024 /PRNewswire/ -- Apollo Medical Holdings, Inc. ("ApolloMed," and together with its subsidiaries and affiliated entities, the "Company") (NASDAQ:AMEH), a leading provider-centric, technology-powered healthcare company enabling providers to deliver accessible, high-quality, and high-value care to all, today announced that it will release financial results for the fourth quarter and full year ended December 31, 2023, after the close of the stock market on Tuesday, February 27, 2024. The Company will discuss those results on a conference call at 2:30 p.m. PT/5:30 p.m. ET that same day.

      1/31/24 8:00:00 AM ET
      $AMEH
      Professional Services
      Consumer Discretionary
    • ApolloMed and BASS Medical Group to Forge a Value-Based Healthcare Partnership

      ALHAMBRA, Calif., Jan. 29, 2024 /PRNewswire/ -- Apollo Medical Holdings, Inc.("ApolloMed," and together with its subsidiaries and affiliated entities, the "Company") (NASDAQ:AMEH), a leading provider-centric, technology-powered healthcare company enabling providers to deliver accessible, high-quality, and high-value care to all, today announced a strategic long-term partnership with BASS Medical Group, one of the largest multi-specialty medical groups in the Greater San Francisco Bay Area. The partnership will bolster BASS Medical Group's value-based care and operational infra

      1/29/24 8:00:00 AM ET
      $AMEH
      Professional Services
      Consumer Discretionary